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Summary
Background—Since the introduction of pandemic influenza A (H1N1) to the USA in 2009, the 
Influenza Incidence Surveillance Project has monitored the burden of influenza in the outpatient 
setting through population-based surveillance.
Methods—From Oct 1, 2009, to July 31, 2013, outpatient clinics representing 13 health 
jurisdictions in the USA reported counts of influenza-like illness (fever including cough or sore 
throat) and all patient visits by age. During four years, staff at 104 unique clinics (range 35–64 per 
year) with a combined median population of 368 559 (IQR 352 595–428 286) attended 35 663 
patients with influenza-like illness and collected 13 925 respiratory specimens. Clinical data and a 
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respiratory specimen for influenza testing by RT-PCR were collected from the first ten patients 
presenting with influenza-like illness each week. We calculated the incidence of visits for 
influenza-like illness using the size of the patient population, and the incidence attributable to 
influenza was extrapolated from the proportion of patients with positive tests each week.
Findings—The site-median peak percentage of specimens positive for influenza ranged from 
58.3% to 77.8%. Children aged 2 to 17 years had the highest incidence of influenza-associated 
visits (range 4.2–28.0 per 1000 people by year), and adults older than 65 years had the lowest 
(range 0.5–3.5 per 1000 population). Influenza A H3N2, pandemic H1N1, and influenza B equally 
co-circulated in the first post-pandemic season, whereas H3N2 predominated for the next two 
seasons. Of patients for whom data was available, influenza vaccination was reported in 3289 
(28.7%) of 11 459 patients with influenza-like illness, and antivirals were prescribed to 1644 
(13.8%) of 11 953 patients.
Interpretation—Influenza incidence varied with age groups and by season after the pandemic of 
2009 influenza A H1N1. High levels of influenza virus circulation, especially in young children, 
emphasise the need for additional efforts to increase the uptake of influenza vaccines and 
antivirals.
Funding—US Centers for Disease Control and Prevention.
Introduction
Influenza viruses circulate during winter months in the USA, causing a sharp increase in 
acute respiratory infections and medically attended illness.1 An estimated 10.6 million 
ambulatory care visits and an associated US$6.8 billion in costs occur during an average 
influenza season.2,3 The intensity of seasonal influenza epidemics can vary substantially 
because of changes in the predominant influenza virus type in circulation and immunity in 
the population.4 Influenza pandemics can greatly increase morbidity and mortality beyond 
that of seasonal influenza,5 often shifting the burden of severe disease from the older adults 
to children and young adults because of their immunological naivity and resulting higher 
attack rates.6 Pandemic influenza viruses usually circulate for several years after the 
pandemic, replacing subtype-specific seasonal influenza viruses.7
To assess the contribution of laboratory-confirmed influenza, both laboratory-based 
virological and medical practice-based clinical surveillance are necessary to establish the 
influenza-attributable proportion of physician consultations for respiratory illness.8 In 2009, 
the US Centers for Disease Control and Prevention (CDC) initiated the Influenza Incidence 
Surveillance Project (IISP) to monitor medically attended influenza-like illness among 
health-care providers with patient populations of estimated size, which allow for incidence 
calculation. We aimed to use IISP data from 2009 to 2013 to investigate the seasonal 
variation in incidence of laboratory-confirmed, medically attended influenza, during the 
2009 influenza A H1N1 pandemic (pH1N1) and the three subsequent influenza seasons.
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Methods
Surveillance population
From Oct 1, 2009, to July 31, 2013, 13 public health departments were engaged to 
participate as sites in IISP: Florida, Iowa, Minnesota, North Dakota, Oregon, Wisconsin, and 
New York City from Oct 1, 2009, to July 31, 2013; New Jersey, Virginia, Los Angeles 
county, and Philadelphia from Aug 1, 2010, to July 31, 2013; Utah from Oct 1, 2009, to July 
31, 2011; and Texas from Aug 1, 2011, to July 31, 2013. Each site recruited about five 
clinics or health-care providers to undertake surveillance providing they accepted acutely ill 
patients, attended roughly 100–150 patients per week, and were able to determine the size of 
their patient population. A detailed description of the methods used to enumerate patient 
populations has been published previously.9 Briefly, clinics reported the number of patients 
registered to their practices or the average number of unique patients seen per year. All age 
groups had to be represented in each jurisdiction participating in surveillance.
Procedures
Patients of all ages who visited participating clinics were assessed for influenza-like illness 
by health-care personnel. For patients aged 2 years or older, influenza-like illness was 
defined as reported or measured fever with cough or sore throat and presentation within 7 
days of onset. For patients younger than 2 years, influenza-like illness was defined as 
reported or measured fever with one or more respiratory symptoms, including cough, sore 
throat, nasal congestion, rhinorrhoea, and onset within 7 days before presentation to clinic; 
for the 2009–10 surveillance year, the symptoms for children younger than 2 years could 
also include decreased appetite, chills, myalgia, and malaise. Clinics reported the number of 
patients with influenza-like illness and the total number of patient visits each week, 
aggregated by age group (<2 years, 2–4 years, 5–17 years, 18–24 years, 25–49 years, 50–64 
years, and ≥65 years).
Respiratory specimens were systematically collected from the first ten patients with 
influenza-like illness visiting the clinic each week and could include nasal, nasopharyngeal, 
or oropharyngeal swabs or nasal aspirates. In view of the small clinic size needed for 
participation in IISP, we decided to sample ten patients at each site to ensure that a large 
portion of, if not all, patients with influenza-like illness attended in a given week would be 
sampled. Demographic and clinical information, including patient-reported symptoms and 
influenza vaccination status were collected during the visit. Clinicians recorded whether 
antivirals were prescribed and reported the results of rapid influenza detection testing 
(RIDT), if done. Respiratory specimens were tested for influenza viruses by use of the CDC 
Human Influenza Virus RT-PCR Diagnostic Panel, which includes influenza A viruses and 
subtypes seasonal H1N1, H1N1pdm09 (pH1N1), H3N2, and influenza B viruses. At the 
Virginia site, specimens were first tested by Luminex xTAG RVP (Luminex Diagnostics, 
Toronto, ON, Canada), then influenza A-positive specimens were subtyped with the CDC 
panel.
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Statistical analysis
We included patients who met the case definition of influenza-like illness and had completed 
PCR testing in the analysis. Each surveillance year was defined as 52 weeks from Aug 1 to 
the following July 31, with the exception of the 2009–10 surveillance year, in which 
surveillance was started in October. The influenza season was defined for each year as all 
consecutive weeks with 10% or more of specimens testing positive for influenza. Health 
department jurisdictions were grouped into the Health and Human Service (HHS) regions—
Region 2 (New York City and New Jersey), Region 3 (Philadelphia and Virginia), Region 4 
(Florida), Region 5 (Minnesota and Wisconsin), Region 6 (Texas), Region 7 (Iowa), Region 
8 (North Dakota, Utah), Region 9 (Los Angeles), and Region 10 (Oregon)10—and we 
calculated the median of each region’s peak week of influenza detection. We compared 
patient demographics, clinical data, and symptoms between patients who were influenza 
test-positive and those who were test-negative using χ2 tests.
To estimate the weekly incidence of influenza-associated visits for each age group, we 
multiplied the total number of visits for influenza-like illness for each week by the 
proportion of patients sampled who were influenza test-positive, and divided by the total 
population of each age group. We summed the weekly incidence for all 52 weeks of each 
surveillance year to obtain the cumulative incidence. We calculated 95% CIs with bootstrap 
sampling from the population of patients with influenza-like illness to account for variance 
in the incidence of influenza-like illness and variance of the percentage of patients who 
might test positive for influenza each week.11 We excluded clinics from incidence 
calculations if population data were missing; fewer than five influenza-like illness visits 
were reported in a year; or if the total of all-cause patient visits, which includes well-visits 
(routine checkups) and follow-up appointments, was less than 10% or more than 600% of 
the estimated source population size. We used SAS version 9.2 for all statistical analyses. 
The IISP uses routinely collected specimens and public health surveillance data therefore 
this study was considered exempt from needing institutional review board approval.
Role of the funding source
The authors from the CDC had a role in study design, data collection, data analysis, data 
interpretation, and writing of the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to submit for publication.
Results
During the four surveillance years, 115 clinics participated in IISP for a total of 247 clinic-
seasons of contributed data. We excluded 32 clinic-seasons from our analysis, which 
resulted in the complete exclusion of 11 clinics. The excluded clinics did not differ 
significantly from included clinics according to clinic type, urbanicity, or funding type. The 
characteristics of the individual clinics included in the analysis varied with participation 
each year, but most were primary care clinics (98 [94.2%] of 104 clinics), including 
paediatric, family medicine, and student health; six (5.8%) clinics were emergency 
departments and urgent care clinics. Overall, 73 (70.2%) clinics were in urban or suburban 
areas, and 45 (43.3%) were publicly funded. The median population under surveillance was 
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368 559 people (IQR 352 595–428 286), and the age distribution was similar to that of the 
US population.12
Participating clinics recorded 2 189 675 visits during the 4 year period, with a median of 152 
patients seen per week (IQR 93–248). Patient visits varied in accordance with clinic 
population size and time of year. Visits for influenza-like illness were reported for 35 663 
patients (1.6% of all visits). Only six clinics had a median of more than ten patients with 
influenza-like illness per week (maximum for sampling), and only 64 clinics had a 
maximum number of patients with influenza-like illness per week that was more than ten, 
representing only 786 (7%) of 10 560 clinic-weeks. The proportion of visits for an 
influenza-like illness peaked at 1229 (12.8%) of 9579 visits in 2009–10, 537 (4.6%) of 
11714 visits in 2010–11, 306 (2.0%) of 15599 visits in 2011–12, and 426 (6.0%) of 7139 
visits in 2012–13, with the peak week occurring between October (pandemic season) and 
March (figure 1).
Respiratory specimens were collected from 20 350 patients, representing 57% of all reported 
visits for influenza-like illness, of which 13 925 (68.4%) met the inclusion criteria. Of 
patients excluded, 5644 did not meet the case definition for influenza-like illness, 449 did 
not have testing completed, and 332 presented more than 7 days after illness onset. Overall, 
influenza was detected in 3890 (27.9%) patients with influenza-like illness, and detection 
ranged by season from 451 (14.1%) of 3203 patients in 2011–12 to 1647 (36.8%) of 4472 
patients in 2012–13 (table 1). For the HHS Regions, the median peak percentage of 
specimens positive for influenza was 75.0% (IQR 63.2–78.0) in 2009–10, 67.9% (60.0–
75.0) in 2010–11, 58.3% (45.2–66.7) in 2011–12, and 77.8% (66.7–82.4) in 2012–13. The 
median duration of the influenza season was 19 weeks (16–21) in 2010–11, 11 weeks (10–
15) in 2011–12 and 20 weeks (20–21) in 2012–13. When sites were aggregated nationally, 
the peak percentage of specimens positive for influenza was lower and the season duration 
was longer than when they were assessed separately (figure 2).
Of the 13 925 specimens collected, 10 199 (73.2%) were nasopharyngeal swabs, 1695 
(12.2%) were oropharyngeal swabs, 1473 (10.6%) were nasal swabs, and 558 (4.0%) were 
nasal aspirates. Influenza detection was higher in nasal aspirates (29.4%) and 
nasopharyngeal swab specimens (29.3%) than in nasal swabs (25.6%) or oropharyngeal 
swabs (21.3%; p<0.0001 for all comparisons).
Influenza A viruses represented the majority of influenza detections from 2009 to 2013 
(table 1), and the distribution of influenza A virus subtypes and influenza B virus varied 
substantially each year (appendix). During the pandemic in 2009–10, most influenza 
detections were 2009 pH1N1, but in 2010–11, there were roughly equal proportions of 
pH1N1, influenza A H3N2, and influenza B viruses in circulation (table 1). In 2011–12, 
H3N2 virus predominated with pH1N1 virus commonly detected; H3N2 predominated again 
in 2012–13, followed by influenza B (table 1). With the exception of 2009–10, influenza 
type A virus usually predominated in the early part of the season with influenza B virus 
predominating in the later weeks (figure 1).
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Influenza accounted for a substantial proportion of influenza-like illness when influenza 
viruses circulated during late autumn and winter (figure 1). After the pandemic season, the 
highest incidence of influenza-like illness visits was in 2012–13 (30.4 per 1000 people, 95% 
CI 30.1–31.0; table 2). The lowest incidence of influenza-like illness visits was in 2011–12 
(14.2 per 1000 people, 13.9–14.5), with a corresponding influenza-associated visit incidence 
rate of 1.9 per 1000 people (1.8–2.0).
The incidence of influenza-associated visits was highest in patients aged 2–4 years and 5–17 
years (range 4.2–28.0 per 1000 people), although for 2009–10 we noted a slight overlap in 
the 95% CIs for children younger than 2 years and aged 2–4 years (table 2). In adults aged 
18 to 24 years, the influenza-associated incidence ranged by year from 1.2 to 13.8 per 1000 
people, and typically decreased further with each subsequent increasing age group. Adults 
aged 65 years or older had the lowest influenza-associated incidence, with the exception of 
2011–12, in which incidence was low in all adult age groups (table 2).
Assessment of subtype-specific differences by age showed that incidence of pH1N1 virus 
infection was highest among patients aged 2–4 and 5–17 years in 2009–10 (table 2). In 
2010–11, the incidence of pH1N1 remained high in paediatric patients aged 2–4 and 5–17 
years, but similar rates were noted for young adults aged 18–24 years. With the exception of 
pH1N1 in the 18–24 year age group in 2010–11, H3N2 was the predominant influenza A 
subtype in adults after 2009–10 (table 2). Influenza B virus incidence was consistently 
highest in children aged 5–17 years, and very low among adults (table 2, figure 3).
With the exception of the case definition inclusion criteria (fever, cough, sore throat), the 
most frequently reported symptoms were congestion (4888 [44.9%] of 10 844), rhinorrhoea 
(6178 [44.8%] of 13 787 patients), and myalgia (4357 [31.6%] of 13 770 patients), which 
were significantly more common in patients who were positive for influenza than in those 
who were negative for it (table 3). Influenza antiviral treatment was reported for 1644 
(13.8%) of 11 953 patients with influenza-like illness. Among those who received antivirals, 
1358 (82.6%) of 1644 patients presented within 2 days of symptom onset and 1371 (86.8%) 
of 1579 patients with data available had a rapid influenza detection test (RIDT). The 
calculated RIDT sensitivity was 56.9% (table 3), and of the 1371 patients with influenza-like 
illness who both received antivirals and had an RIDT done, 946 (69.0%) were influenza-
positive by RT-PCR. Overall, low proportions of patients reported influenza vaccination 
(3289 [28.7% (SD 0.8)] of 11 459 patients). Influenza vaccination was most prevalent in 
2011–12 (32.7% [SD 1.7]) compared with other years (25.9 [2.2]) in 2009–10, 27.7 [1.6] in 
2010–11, and 27.7 [1.4] in 2012–13, p<0.0001). Children (ages 17 years and younger) were 
significantly more likely to have been vaccinated than were adults (relative risk 1.3, 
p<0.0001); irrespective of age, vaccination was significantly more common in patients 
negative for influenza than in those who were influenza-positive (table 3).
Discussion
The IISP is the only nationally representative programme to do year-round, population-
based surveillance for medically attended influenza-like illness that incorporates RT-PCR 
testing for influenza. This integrated syndromic and virological surveillance system allows 
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estimation of influenza incidence from a systematic sample of medically-attended influenza-
like illness visits from a well-characterised patient population. Previous population-based 
studies incorporating laboratory confirmation of influenza have established the tremendous 
burden of influenza in the outpatient setting, but do not represent more recent data.13,14 
Influenza disease burden modelling has therefore relied on estimation of medically-attended 
illness associated with influenza from combined sources.15 However, the annual variation of 
influenza subtype circulation and effect, especially in view of the 2009 influenza A (H1N1) 
pdm09 (pH1N1) pandemic, necessitates systematic, year-round surveillance from a source 
population to estimate the burden of medically attended influenza infections each year. We 
noted that from 2009 to 2013, influenza accounted for 28% of all influenza-like illness 
visits, ranging from 58–78% during peak periods of influenza circulation by geographical 
regions. Influenza incidence varied widely by year with a five-times difference in incidence 
between 2011–12 and 2012–13, in which H3N2 predominated. The highest incidence of 
influenza-like illness was among children younger than 5 years, and the highest incidence of 
influenza was among children aged 2–17 years. Prevalence of influenza vaccination was low 
in the IISP population, as was prevalence of antiviral prescribing without a positive RIDT.
The emergence of pH1N1 virus in 2009 caused high morbidity, with roughly 1 in 100 people 
in the USA being medically attended for influenza. In subsequent years, pH1N1 continued 
to circulate, with variable estimates of associated medically attended influenza-like illness. 
In 2010–11 influenza virus circulation was divided almost equally between pH1N1, H3N2, 
and influenza B viruses. Co-circulation of all three viruses happened again in 2011–12, with 
a predominance of H3N2 virus, and a low overall incidence of influenza-like illness; the 
season was mild in both the USA and Europe.16,17 After 3 years of low H3N2 virus 
incidence, the 2012–13 season was characterised by a high incidence of H3N2 virus 
circulation and high incidence of medically attended illness, similar to the pandemic season. 
Previous studies have established that H3N2 is associated with more severe illness than 
other subtypes in elderly adults and young children,18,19 and during the 2012–13 season, 
routine CDC surveillance systems reported some of the highest rates of influenza-related 
hospitalisation and death reported in the past decade.20
After the pandemic, we detected an age shift in peak pH1N1 incidence from children aged 
2–17 years to equal incidence in children and young adults (ages 2–24 years), which was 
similarly recorded in Europe in 2010–11.6 This shifting age distribution was also described 
after the 1918 and 1957 influenza pandemics.21 Increased incidence of influenza during the 
first wave of an influenza pandemic might result from heightened attack rates in 
immunologically naive children during the first wave of a pandemic, leaving a larger 
proportion of adults relatively more susceptible in subsequent waves and seasons compared 
with children.21 In IISP, the incidence of pH1N1 among adults aged 65 years older was very 
low from 2009–10 onwards, which supports the notion that older adults possess cross-
reactive immunity from previous, antigenically similar H1N1 infections.22
With the exception of the 2009 pandemic, both the proportion of specimens positive for 
influenza and the incidence of influenza-associated visits were consistently high in children 
aged 5–17 years. By contrast, influenza was frequently detected in adults, but the incidence 
of influenza-like illness visits was much lower than in children, yielding an overall lower 
Fowlkes et al. Page 8
Lancet Respir Med. Author manuscript; available in PMC 2018 January 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
incidence of medically attended influenza. This divergence of incidence and detection in 
adults is consistent with population-based surveillance done during the Tecumseh Study of 
Respiratory Illness, and studies of influenza detection in adults.23,24
Influenza vaccination and antiviral drugs are currently the most effective strategies to 
prevent influenza and treat its complications, yet neither was commonly reported in the IISP 
population. For example in 2011–12, after recommendations for universal vaccination, we 
saw that 36.9% of children and 25.8% of adults reported vaccination, which was lower than 
the national survey estimates of 51.5% among children and 38.8% adults.25 Antiviral drugs 
for influenza were usually only prescribed for patients who had a positive RIDT and who 
presented within 2 days of illness onset. Although RIDTs have been shown repeatedly to 
have a low sensitivity and empirical use is recommended for patients at risk of 
complications,26,27 health-care providers continue to rely on their results to guide clinical 
treatment.
The IISP network addresses many challenges of population-based influenza surveillance, but 
was subject to limitations. The initial 2009–10 surveillance year began as pH1N1 circulation 
reached its peak phase, so the cumulative incidence of influenza-like illness visits 
attributable to influenza represents only about half of the season and actual burden of 
pandemic influenza. Estimates for 2009–10 were not modified because attempts to do so 
would introduce unmeasurable bias, but trends seen in the age differential should not be 
affected. We used the patient population as an approximation of the community to estimate 
incidence, rather than a census tract or catchment area. Our previous assessments have 
shown that this strategy is valid,28 and similar strategies have been used successfully for 
many years in other countries in accordance with WHO recommendations for establishing 
denominators in sentinel influenza surveillance programmes.29 For example, the UK’s 
general practitioner surveillance provides a comparable representation of medically attended 
influenza-like illness incidence.30 IISP represents non-identifiable surveillance data, so 
underlying medical conditions could not be ascertained and individuals with more than one 
clinical visit during an illness cannot be differentiated from those with only one visit; 
therefore, it should be noted that our study reports prescription of antivirals for all 
individuals and the incidence of clinical visits rather than for individual infections. The age 
distribution of the IISP population was similar to that of the USA, but additional 
demographic factors and health-care seeking behaviours could not be assessed. Identification 
of patients aged 65 years or older was low, but representative of differences in primary care 
use and incidence of influenza-like illness by age.31 Notably, we used the case definition of 
influenza-like illness for surveillance to conserve resources and guide diagnostic testing, but 
it does not represent the full scope of influenza illness; therefore, we hope that the incidence 
of visits for influenza-associated influenza-like illness presented in this report will inform 
studies to estimate the much broader scope of influenza disease burden.
The IISP is the only multistate, nationally representative network that can estimate influenza 
incidence in patients with influenza-like illness presenting to ambulatory care clinics in the 
USA. The consistency of these data over multiple years allowed us to show the introduction 
and subsequent sea sonal circulation of pH1N1 in the USA. Children aged 2–17 years 
consistently had the highest incidence of influenza-associated visits, but young adults were 
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substantially affected in the first and second years of 2009 pandemic influenza A H1N1 
pH1N1 virus circulation. The data also provide insight into vaccination coverage in the 
outpatient setting, antiviral prescribing practices, and the effect of changing seasonal 
influenza strain predominance on the number of recorded influenza-associated visits. The 
low prevalence of influenza vaccination and antiviral treatment reported through IISP 
suggest that continued emphasis is needed on communication efforts about the benefits of 
these preventive measures.
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Research in context
Evidence before this study
The aim of the Influenza Incidence Surveillance Project (IISP) was to establish in the 
USA a population-based surveillance system to monitor influenza-like illness and 
determine the proportion attributable to influenza. The current study contextualises the 
findings of the IISP during the 2009 H1N1 pandemic and subsequent years. To support 
the current study, we searched PubMed using the terms “pandemic influenza burden by 
age”, with no language or date restrictions, up to Feb 1, 2015. We also used information 
from the US Centers for Disease Control and Prevention (CDC) website. We identified 
140 papers published and highlight two robust studies. The FluWatch cohort study 
(Hayward and colleagues, 2014) presented the disease burden of 2009 pandemic 
influenza A H1N1 in England, Simonsen and colleagues (1998) presented a summary of 
previous influenza pandemics in the 20th century. Both studies described the burden of 
pandemic influenza-associated illness and reported a shift in disease burden from the 
youngest age groups during a pandemic, to a combination of both children and adults in 
the following years.
Added value of this study
Our programme contributes to estimation of the disease burden of influenza types and 
subtypes, and is the first, to our knowledge, to describe the shift in the age-specific 
burden of 2009 pandemic influenza A H1N1 (pH1N1) from the children aged 2–17 years 
in the pandemic year, to include young adults in the following year among US 
outpatients. The IISP is the only continuous, multistate US programme that does 
population-based surveillance for medically-attended influenza-like illness and tests for 
influenza. Our report further describes the low prevalence of influenza vaccination in the 
IISP population and uncommon antiviral prescribing, including in the age groups judged 
to be at high risk for influenza complications.
Implications of all the available evidence
Enhanced surveillance for influenza in the USA provides insight into the effect of 
changes in influenza strain predominance on the incidence of influenza-associated 
outpatient visits. These data can be applied to disease burden models to estimate the total 
effect of influenza disease each year. The low prevalence of influenza vaccination and 
antiviral treatment reported through IISP suggest that continued emphasis on 
communication efforts about the benefits of these preventive measures is needed.
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Figure 1. Incidence per week
Weekly incidence of medically attended influenza-like illness and influenza virus types and 
subtypes.
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Figure 2. Influenza-like illnesses RT-PCR-positive for influenza virus
Data are sorted by US Department of Health and Human Services region and season.
Fowlkes et al. Page 14
Lancet Respir Med. Author manuscript; available in PMC 2018 January 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Influenza incidence by age and subtype
Extrapolated cumulative incidence of PCR-confirmed influenza infection per 1000 
population per surveillance year by age group, influenza type, and subtype, and influenza 
season, from October, 2009, to July, 2013. The percentage of patients who tested positive for 
influenza each week was multiplied by the total number of influenza-like illness visits 
reported for each week and age group, then divided by the corresponding population size. 
The incidence rates each week were added to give the cumulative incidence of influenza-
associated influenza-like illness visits by age group. Surveillance was from October, 2009, 
to July, 2010 and all other subsequent seasons include August to July of the following year.
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Table 3
Demographic and clinical characteristics among outpatients with influenza-like illness
All patients
(n=13 905)*
Influenza-positive
(n=3887)*
Influenza-negative
(n=10 018)*
p value
Age (years) <0–0001
 <2 1825/13 905 (13.1%) 210/3884 (5.4%) 1615/10 015 (16.1%)
 2–4 2026/13 905 (14.6%) 431/3884 (11.1%) 1595/10 015 (15.9%)
 5–17 4409/13 905 (31.7%) 1589/3884 (40.9%) 2820/10 015 (28.2%)
 18–24 2062/13 905 (14.8%) 611/3884 (15.7%) 1451/10 015 (14.5%)
 25–49 2480/13 905 (17.8%) 752/3884 (19.4%) 1728/10 015 (17.3%)
 50–64 790/13 905 (5.7%) 199/3884 (5.1%) 591/10 015 (5.9%)
 ≥65 307/13 905 (2.2%) 92/3884 (2.4%) 215/10 015 (2.1%)
Male 6336/13 752 (46.1%) 1846/3848 (48.0%) 4490/9904 (45.3%) 0.0053
Ethnic origin 0.0312
 White, non-Hispanic 6553/9857 (66.5%) 1752/2656 (66.0%) 4801/7201 (66.7%)
 Black, non-Hispanic 1331/9857 (13.5%) 360/2656 (13.6%) 971/7201 (13.5%)
 Hispanic 1369/9857 (13.9%) 349/2656 (13.1%) 1020/7201 (14.2%)
 Asian 323/9857 (3.3%) 107/2656 (4.0%) 216/7201 (3.0%)
 Other 281/9857 (2.9%) 88/2656 (3.3%) 193/7201 (2.7%)
RIDT done 10 567/12 942 (81.6%) 3219/3693 (87.2%) 7348/9249 (79.4%) <0.0001
 RIDT positive 23 64/10 535 (22.4%) 1831/3216 (56.9%) 533/7319 (7.3%) <0.0001
Antivirals prescribed 1644/11 953 (13.8%) 1119/3304 (33.9%) 525/8643 (6.1%) <0.0001
 Patients with onset ≤2 days 1358/7727 (17.6%) 946/2206 (42.9%) 412/5521 (7.5%) <0.0001
 RIDT-positive patients 890/1918 (46.4%) 795/1589 (50.0%) 95/1134 (8.4%) <0.0001
Influenza vaccination†
 Age <18 years 2176/6947 (31.3%) 422/1812 (23.3%) 1754/5135 (34.2%) <0.0001
 Age ≥18 years 1113/4512 (24.7%) 301/1331 (22.6%) 812/3181 (25.5%) 0.385
Symptoms
 Cough 11 362/13 889 (81.8%) 3600/3887 (92.6%) 7762/10 002 (77.6%) <0.0001
 Sore throat 8444/13 810 (61.1%) 2384/3856 (61.8%) 6060/9954 (60.9%) 0.3064
 Rhinorrhoea 6178/13 787 (44.8%) 1946/3861 (50.4%) 4232/9926 (42.6%) <0.0001
 Myalgia 4357/13 770 01.6%) 1615/3857 (41.9%) 2742/9913 (27.7%) <0.0001
 Congestion 4888/10 884 (44.9%) 1471/2979 (49.4%) 3417/7905 (43.2%) <0.0001
 Earache 1237/9993 (12.4%) 296/2746 (10.8%) 941/7247 (13.0%) 0.0028
 Chills 3460/12 474 (27.7%) 1239/3434 (36.1%) 2221/9040 (24.6%) <0.0001
Data are n/N (%) unless otherwise indicated. RIDT=rapid influenza detection test.
*Variation in denominator because of missing information for some patients.
†
Influenza vaccination status reported by patients at the time of clinical consultation.
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